Literature DB >> 2317754

Osteonecrosis in pediatric patients with acute lymphoblastic leukemia.

R G Murphy1, M L Greenberg.   

Abstract

The authors report five pediatric patients with acute lymphoblastic leukemia (ALL) in whom symptomatic aseptic osteonecrosis developed on therapy. All patients had been on treatment with a modified BFM protocol and developed osteonecrosis in the maintenance phase of the protocol. The avascular necrosis was multifocal in all. The authors' data suggest that dexamethasone used in the reinduction phase of the protocol may be the responsible agent although no definite proof exists. Since only symptomatic patients are reported, the true frequency of this complication may be significantly higher.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2317754     DOI: 10.1002/1097-0142(19900415)65:8<1717::aid-cncr2820650809>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

Review 1.  Minimising the long-term adverse effects of childhood leukaemia therapy.

Authors:  Claudia Langebrake; Dirk Reinhardt; Jörg Ritter
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

2.  [Osteonecrosis after chemotherapy in children].

Authors:  B Westhoff; M Jäger; R Krauspe
Journal:  Orthopade       Date:  2008-01       Impact factor: 1.087

3.  On a case of multifocal osteonecrosis in a patient suffering from acute lymphoblastic leukemia.

Authors:  Giuseppe Solarino; Lorenzo Scialpi; Marco Bruno; Berenice De Cillis
Journal:  Chir Organi Mov       Date:  2008-05-12

4.  Symptomatic osteonecrosis in childhood leukemia survivors: prevalence, risk factors and impact on quality of life in adulthood.

Authors:  Pauline Girard; Pascal Auquier; Vincent Barlogis; Audrey Contet; Maryline Poiree; François Demeocq; Julie Berbis; Iris Herrmann; Virginie Villes; Nicolas Sirvent; Justyna Kanold; Pascal Chastagner; Hervé Chambost; Dominique Plantaz; Gérard Michel
Journal:  Haematologica       Date:  2013-05-03       Impact factor: 9.941

5.  Bisphosphonate Therapy for Treating Osteonecrosis in Pediatric Leukemia Patients: A Systematic Review.

Authors:  Shanaz M Daneshdoost; Jad M El Abiad; Kathy J Ruble; Lynne C Jones; Janet L Crane; Carol D Morris; Adam S Levin
Journal:  J Pediatr Hematol Oncol       Date:  2021-04-01       Impact factor: 1.289

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.